Clinical Utility of Optim.AI™ Precision Oncology Recommendations in Refractory Haematological Malignancies July 24, 2026
Clinical application of functional precision medicine for pancreatic cancer enables personalized treatment prioritization and identification of RAS-targeted combinations September 25, 2026
Functional Precision Medicine Identifies Oral Fluoropyrimidine Sensitivity in Heavily Pretreated Metastatic Breast Cancer: A Case Report July 05, 2026
Clinical feasibility study of Optim.AI 2.0, a co-culture high-content functional precision platform for predicting combinatorial immunotherapy response April 17, 2026
Real-world concordance analysis of functional drug sensitivity testing in solid cancers with prospective observational case series of pancreatic cancer April 17, 2026
Real-world clinical performance of a combinatorial functional precision platform, Optim.AI™, in hematological malignancies April 17, 2026
Feasibility study of an ex vivo functional precision medicine platform, Optim.AI™, in guiding treatment for gynecological cancers April 17, 2026
Applying a functional precision medicine platform, Optim.AI, to identify novel KRAS inhibitor-based combinations in pancreatic cancer March 06, 2026
Functional precision medicine assay identifies patients with relapsed/refractory Soft Tissue Sarcoma who benefit from Bortezomib-based therapy March 14, 2026
Clinical evaluation of a high-content functional precision medicine platform for predicting immunotherapy combination response February 19, 2026
